Business Description
Laurus Labs Ltd
ISIN : INE947Q01028
Compare
Compare
Traded in other countries / regions
540222.India IPO Date
2016-12-19Description
Laurus Labs Ltd is a pharmaceutical company based in India. It provides active pharmaceuticals ingredients (API) including intermediates, Generic Finished dosage forms (FDF) and Contract Research services. The entity develops APIs and intermediates for select, high-growth antiretrovirals, Hepatitis C and Oncology. It also manufactures APIs in other therapeutic areas, such as anti-asthma, ophthalmology, anti-diabetics, cardiovascular, proton pump inhibitors, among others. The company has its business presence in India and Outside India of which it derives a majority of revenue from Outside India. It generates revenue from the sale of API, Intermediates and Formulations, Contract research services and others.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.02 | |||||
| Equity-to-Asset | 0.47 | |||||
| Debt-to-Equity | 0.68 | |||||
| Debt-to-EBITDA | 3.53 | |||||
| Interest Coverage | 1.88 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 4.23 | |||||
| Beneish M-Score | -2.79 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 1.8 | |||||
| 3-Year EBITDA Growth Rate | -20.3 | |||||
| 3-Year EPS without NRI Growth Rate | -46.7 | |||||
| 3-Year Book Growth Rate | 16.4 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 72.57 | |||||
| Future 3-5Y Total Revenue Growth Rate | 14.29 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 91.03 | |||||
| 9-Day RSI | 83.2 | |||||
| 14-Day RSI | 76.51 | |||||
| 6-1 Month Momentum % | 11.01 | |||||
| 12-1 Month Momentum % | 30.38 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.19 | |||||
| Quick Ratio | 0.58 | |||||
| Cash Ratio | 0.01 | |||||
| Days Inventory | 292.6 | |||||
| Days Sales Outstanding | 120.39 | |||||
| Days Payable | 156.22 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.14 | |||||
| Dividend Payout Ratio | 0.33 | |||||
| 3-Year Dividend Growth Rate | 4.6 | |||||
| Forward Dividend Yield % | 0.14 | |||||
| 5-Year Yield-on-Cost % | 0.79 | |||||
| 3-Year Average Share Buyback Ratio | -0.1 | |||||
| Shareholder Yield % | -2.16 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 51.75 | |||||
| Operating Margin % | 7.18 | |||||
| Net Margin % | 2.62 | |||||
| FCF Margin % | -0.25 | |||||
| ROE % | 3.2 | |||||
| ROA % | 1.56 | |||||
| ROIC % | 3.56 | |||||
| ROC (Joel Greenblatt) % | 5.9 | |||||
| ROCE % | 7.19 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 226.94 | |||||
| Forward PE Ratio | 79.42 | |||||
| PE Ratio without NRI | 226.94 | |||||
| Shiller PE Ratio | 59.65 | |||||
| PEG Ratio | 10.46 | |||||
| PS Ratio | 5.94 | |||||
| PB Ratio | 7.19 | |||||
| Price-to-Tangible-Book | 7.89 | |||||
| Price-to-Operating-Cash-Flow | 44.7 | |||||
| EV-to-EBIT | 88.75 | |||||
| EV-to-EBITDA | 42.19 | |||||
| EV-to-Revenue | 6.63 | |||||
| EV-to-FCF | -2292.14 | |||||
| Price-to-Projected-FCF | 8.29 | |||||
| Price-to-DCF (Earnings Based) | 10.28 | |||||
| Price-to-Peter-Lynch-Fair-Value | 31.77 | |||||
| Price-to-Graham-Number | 9.05 | |||||
| Earnings Yield (Greenblatt) % | 1.13 | |||||
| FCF Yield % | -0.05 | |||||
| Forward Rate of Return (Yacktman) % | 20.15 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Laurus Labs Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 50,141.7 | ||
| EPS (TTM) (₹) | 2.43 | ||
| Beta | 1.05 | ||
| Volatility % | 29.94 | ||
| 14-Day RSI | 76.51 | ||
| 14-Day ATR (₹) | 17.0792 | ||
| 20-Day SMA (₹) | 505.98 | ||
| 12-1 Month Momentum % | 30.38 | ||
| 52-Week Range (₹) | 358.7 - 570.45 | ||
| Shares Outstanding (Mil) | 539.16 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Laurus Labs Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Laurus Labs Ltd Stock Events
| Event | Date | Price(₹) | ||
|---|---|---|---|---|
| No Event Data | ||||
Laurus Labs Ltd Frequently Asked Questions
What is Laurus Labs Ltd(BOM:540222)'s stock price today?
The current price of BOM:540222 is ₹566.70. The 52 week high of BOM:540222 is ₹570.45 and 52 week low is ₹358.70.
When is next earnings date of Laurus Labs Ltd(BOM:540222)?
The next earnings date of Laurus Labs Ltd(BOM:540222) is 2025-01-24 Est..
Does Laurus Labs Ltd(BOM:540222) pay dividends? If so, how much?
The Dividend Yield %  of Laurus Labs Ltd(BOM:540222) is 0.14% (As of Today), Highest Dividend Payout Ratio of Laurus Labs Ltd(BOM:540222) was 0.58. The lowest was 0.08. And the median was 0.13. The  Forward Dividend Yield % of Laurus Labs Ltd(BOM:540222) is 0.14%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers